Diligence memo · auto-generated · as of July 2, 2026
Biolex Therapeutics, Inc.
Biolex Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Biolex Therapeutics, Inc. operates in Biotechnology, based in PITTSBORO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biolex Therapeutics, Inc. has raised $27M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2010-02-11.
Most recent recorded round closed around 2011-12-06.
Valuation (modeled)modeled
Provath models Biolex Therapeutics, Inc. at approximately $85M (range $2.6M–$465M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.43× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 14.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 73% of Biotechnology peers (4293 compared).
Modeled value ranks above 55% of those peers.
Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.